- Location
Avastin
"-
Data Show Treatment Prolongs Life for Women with Most Common Cancer in Under 35s
Feb 27, 2014Data published in New England Journal of Medicine show treatment prolongs life for women with most common cancer in under 35s New data showing cancer treatment Avastin® (bevacizumab) can extend the lives of women with advanced ...
Tags: Cervical Cancer, Avastin, GOG240, GOG
-
Clinical Trials Investigating New Uses Have Produced Mixed Results
Feb 19, 2014Clinical trials investigating new uses for the anti-cancer drug Avastin have produced mixed results. When combined with standard chemotherapy, Avastin extended the survival of patients with advanced cervical cancer by nearly four months, ...
-
More Than 90% of The Patients Treated with The Vaccine Candidate Were Alive at Six Months
Jan 21, 2014Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma ...
-
Women Fighting an Aggressive Form of Breast Cancer May Benefit From Adding Certain Drugs
Dec 25, 2013Women fighting an aggressive form of breast cancer may benefit from adding certain drugs to their chemotherapy regimen, and taking them prior to surgery, new research finds. This pre-surgical drug therapy boosts the likelihood that no ...
-
Tracon Has Started Dosing in a Phase Ib Clinical of TRC105 for The Treatment of Patients
Sep 25, 2013US-based biopharmaceutical firm Tracon Pharmaceuticals has started dosing in a Phase Ib clinical of TRC105 for the treatment of patients with metastatic renal cell carcinoma. The trial evaluates the combination of TRC105 and a standard ...
Tags: Tracon, Carcinoma Drug
-
Oncobiologics and InVentiv Have Formed a Partnership for Development of Biosimilar Assets
Aug 9, 2013Oncobiologics and inVentiv Health have formed a global, strategic partnership for clinical development of biosimilar assets initially with a probable expansion to new molecules. The biosimilar assets include generic versions of Humira, ...
Tags: Oncobiologics, Biosimilars
-
MHLW as a Combination Therapy and Monotherapy to Treat Aggressive Form of Brain Cancer
Jun 19, 2013The Japanese Ministry of Health, Labour and Welfare (MHLW) has cleared Roche's Avastin (bevacizumab) as a combination therapy and monotherapy to treat the aggressive form of brain cancer glioblastoma. The first new medicine that is ...
Tags: Glioblastoma Therapy, Medicine
-
A New Study Has Looked at Whether an Individual Is Likely to Develop AMD
Feb 19, 2013A new study has looked at how certain gene variants may predict whether an individual is likely to develop age-related macular degeneration (AMD). This eye disease affects over nine million Americans, but it has been found that certain ...
-
Cancer Therapeutics Announced The Validation and Performance of CTx-294886
Nov 29, 2012Cancer Therapeutics has announced the validation and performance of CTx-294886 in combination with Avastin in a preclinical model of basal breast cancer. The CTx-0294886, a potent small molecule inhibitor of Focal Adhesion Kinase (FAK) ...
Tags: cancer therapeutics, CTx-294886, basal breast cancer, FAK inhibitor
-
AbD Serotec to Introduce HuCAL Anti-Drug Antibodies Supporting Development of Therapeutics
Nov 28, 2012AbD Serotec, MorphoSys' division for research and diagnostic antibodies, is set to introduce a series of the human combinatorial antibody library (HuCAL) anti-drug antibodies supporting the development of novel antibody therapeutics. The ...
Tags: AbD Serotec, HuCAL Anti-Drug Antibodies, antibody therapeutics, MorphoSys
-
Canadian Intellectual Property Office Issue a Patent for Lorus Cancer Immunotherapy Agent
Jul 2, 2012The Canadian Intellectual Property Office has issued a patent for Lorus Therapeutics' cancer immunotherapy agent, IL-17E. The patent protects the use of IL-17E to treat cancer, including solid tumors such as colon, breast, ovarian, ...
Tags: patent, IL-17E, treatment of cancer
